["{\n\"step_by_step_thinking\": \"According to the article 'Advances in the control of chemotherapy-induced emesis', metoclopramide-containing combination regimens are used for the control of chemotherapy-induced emesis. In this specific study, Group A patients received metoclopramide 0.5 mg/kg four times daily on days 2-5 plus dexamethasone. This regimen showed a higher complete protection from delayed emesis compared to other groups. Therefore, the antiemetic action of metoclopramide is due to its M3 antagonist property.\",\n\"answer_choice\": \"D\"\n}"]